Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00374881 | A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects | PHASE1 | COMPLETED | 9 | — | — | Sep 1, 2006 | Aug 1, 2007 | Apr 15, 2008 | 2 | Israel |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Morphine High Dose |
| 2 | PLACEBO_COMPARATOR | Morphine Low Dose |
| 3 | PLACEBO_COMPARATOR | Sorbitol Phenylephrine |
| 4 | EXPERIMENTAL | Sorbitol high concentration+Phenylephrine+Morphine |
| 5 | EXPERIMENTAL | Sorbitol low concentration+Phenylephrine+Morphine |
| Name | Type | Description |
|---|---|---|
| Morphine | DRUG | Morphine |
| Sorbitol+Phenylephrine | DRUG | Sorbitol+Phenylephrine |
| Sorbitol+Phenylephrine+Morphine | DRUG | Sorbitol+Phenylephrine+Morphine |
| Sorbitol low concentration+Phenylephrine+Morphine | DRUG | Sorbitol low concentration+Phenylephrine+Morphine |
Inclusion Criteria: * Ability to provide written informed consent * Healthy male or female between 18 and 40 years of age, inclusive. * Women have to test negative for pregnancy. * Body weight within 15% of ideal body weight based on Metropolitan Life assurance tables. * No concomitant medications ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | NA | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | — | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | — | Flozin |